Research Analysts Offer Predictions for PMN Q2 Earnings

Promis Neurosciences (NASDAQ:PMN) – HC Wainwright upped their Q2 2026 earnings per share estimates for shares of Promis Neurosciences in a report released on Monday, June 8th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($1.01) for the quarter, up from their previous estimate of ($1.54). HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. HC Wainwright also issued estimates for Promis Neurosciences’ Q3 2026 earnings at ($1.13) EPS, Q4 2026 earnings at ($1.20) EPS, FY2026 earnings at ($4.57) EPS, Q1 2027 earnings at ($1.14) EPS, Q2 2027 earnings at ($0.75) EPS, Q3 2027 earnings at ($0.70) EPS, Q4 2027 earnings at ($0.86) EPS and FY2027 earnings at ($3.33) EPS.

Other equities research analysts have also recently issued research reports about the stock. Wall Street Zen upgraded shares of Promis Neurosciences from a “strong sell” rating to a “sell” rating in a report on Sunday, May 31st. Brookline Capital Markets upgraded shares of Promis Neurosciences to a “strong-buy” rating in a research note on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $26.50.

Promis Neurosciences Stock Up 0.3%

PMN opened at $9.74 on Wednesday. The firm has a 50 day moving average price of $11.03 and a 200-day moving average price of $12.03. Promis Neurosciences has a twelve month low of $6.27 and a twelve month high of $39.75. The stock has a market capitalization of $87.37 million, a price-to-earnings ratio of -0.67 and a beta of -0.19.

Promis Neurosciences (NASDAQ:PMN) last posted its earnings results on Tuesday, May 12th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.06) by ($0.20).

Institutional Trading of Promis Neurosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Seven Fleet Capital Management LP bought a new position in Promis Neurosciences in the first quarter worth approximately $135,000. Janus Henderson Group PLC bought a new stake in shares of Promis Neurosciences during the 1st quarter valued at $16,418,000. Ally Bridge Group NY LLC grew its position in shares of Promis Neurosciences by 66.1% during the 1st quarter. Ally Bridge Group NY LLC now owns 414,219 shares of the company’s stock valued at $5,261,000 after acquiring an additional 164,880 shares during the period. Yu Fan purchased a new stake in shares of Promis Neurosciences in the 1st quarter worth $4,188,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Promis Neurosciences in the 1st quarter worth $1,211,000. 50.13% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Promis Neurosciences news, Director Patrick D. Kirwin purchased 4,000 shares of Promis Neurosciences stock in a transaction dated Wednesday, April 22nd. The stock was purchased at an average price of $11.33 per share, with a total value of $45,320.00. Following the transaction, the director directly owned 4,653 shares of the company’s stock, valued at $52,718.49. This trade represents a 612.56% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.50% of the stock is currently owned by corporate insiders.

About Promis Neurosciences

Promis Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis.

Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation.